Spyre Therapeutics, Inc. (SYRE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$88.98+1.98%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SYRE
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue enrollment and data readouts for SKYLINE (SPY001, SPY002, SPY003, combinations) and SKYWAY (SPY072 in RA, PsA, axSpA) with six expected Phase 2 proof-of-concept readouts in 2026.
Stated as a priority in 3 of last 3 quarters. Management consistently emphasized advancing the Phase 2 SKYLINE and SKYWAY trials with six expected proof-of-concept readouts in 2026, including RA sub-study data in Q3 and SPY003 data in Q3. The timeline and trial enrollment progress reported match these commitments, indicating delivery on this priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Remain on track for 6 proof-of-concept Phase 2 readouts in 2026, with RA sub-study in SKYWAY and SPY003 Part A data from SKYLINE expected in September.”
“Topline data for SPY072 in PsA and axSpA on track for Q4 2026; SPY003 SKYLINE Part A data expected in Q3 2026.”
“Remain on track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials.”
Focus on developing next-generation long-acting antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases with potential for improved efficacy and dosing convenience.
Stated as a priority in 3 of last 3 quarters. Management consistently emphasizes development of long-acting antibodies for IBD and rheumatic diseases, supported by ongoing clinical trials of SPY001, SPY002, SPY072, and SPY003. The clinical progress and trial data releases align with this strategic focus, indicating ongoing delivery.
“Committed to developing next-generation therapies that elevate the standard in immunology by delivering more complete disease control, greater durability, and simpler treatment experience.”
“SPY001, SPY002, SPY072, and SPY003 are highly potent, selective investigational antibodies engineered with half-life extension technology for infrequent dosing.”
“Pioneering long-acting antibodies and antibody combinations to redefine the standard of care in IBD and rheumatic diseases.”
Manage financial resources prudently to sustain operations with cash, cash equivalents, and marketable securities sufficient to fund activities into the second half of 2029.
Stated as a priority in 3 of last 3 quarters. Management reported cash and marketable securities increasing from $777.8 million at 2025-Q4 to $1.1 billion at 2026-Q2, supporting an expected cash runway into the second half of 2029. This financial position aligns with management's stated goal of maintaining financial strength, indicating delivery on this priority.
“$1.1 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, with expected runway into second half of 2029.”
“$1.2 billion in pro forma cash, cash equivalents, and marketable securities as of March 31, 2026, with expected runway into second half of 2029.”
“Cash and marketable securities totaled $777.8 million as of December 31, 2025.”
Advance clinical development of SPY072 in rheumatic diseases including RA, PsA, and axSpA, with topline data readouts and assessment of monotherapy and combination potential.
Stated as a priority in 2 recent disclosures. Management reported RA sub-study topline data for SPY072 with statistically significant efficacy but decided not to prioritize monotherapy development in RA. PsA and axSpA sub-study data remain expected in Q4 2026. This reflects active evaluation and prioritization consistent with management's stated approach.
“RA sub-study topline proof-of-concept data expected in September 2026; PsA and axSpA sub-studies expected in Q4 2026.”
Complete Part A induction data readouts and enroll Part B randomized placebo-controlled cohorts for monotherapies and combinations with multiple proof-of-concept readouts expected in 2026 and 2027.
Over the trailing year it converted 0.72x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.